Vancouver-based Contextual Genomics has launched two molecular hotspot assays for detecting genomic mutations in blood and solid tumors. <!--//--><![CDATA[// ><!-- document.addEventListener("googletagEvent", function () { let hideOnMobile = "0"; let isMobileQuery = false; if (typeof window.dataLayerValues === "undefined" || !window.dataLayerValues.hasOwnProperty('isMobileQuery') || window.dataLayerValues.isMobileQuery) { isMobileQuery = window.dataLayerValues.isMobileQuery; } // Don't display the ad unit if this is a mobile browser and we're supposed to hide the unit in mobile view. if (isMobileQuery && hideOnMobile === '1') { return; } let hideOnDesktop = "0"; // Don't display this ad unit if this is a desktop broser and we're supposed to hide the mobile ad unit if(!isMobileQuery && hideOnDesktop === '1') { return; } googletag.cmd.push(function () { googletag.display('content-embed-one'); }); }); //--><!]]> The new version of the company’s Find It solid tumor panel now screens for 146 somatic genome alterations, and 23 exons in 30 cancer-associated genes, to help identify precision cancer treatments and recognize drug-resistant mutations. New additions to the panel include tests for mutations in the POLE gene, which have been associated with colorectal cancer as well as immunodeficiency.